Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Evommune, Inc.NYSE: EVMN
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 300.0% from a year ago
Common stock stood at $4K at the end of Q1 FY2026, up 300.0% from a year earlier and up 33.3% from the prior quarter.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +300.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 3K USD
- Year-over-year change
- +200.0%
- 2-year CAGR
- +73.2%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3K | +200.0% |
| FY2024 | 2024-12-31 | 1K | +0.0% |
| FY2023 | 2023-12-31 | 1K | — |
Common Stock vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 common stock of $4K is the 9th highest of the 10 companies compared; the peer median is $14K.
- Its year-over-year change of +300.0% is the highest of 10, against a peer median of +4.2%.
- Common stock amounts to 0.0% of total assets for EVMN, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.15B | +4.2% | +7.1% | 97.5% | |
FTREFortrea Holdings Inc. | Jun 2026 | $100K | +0.0% | — | 0.0% |
| Mar 2026 | $83K | +20.3% | +34.6% | 0.0% | |
| Jun 2026 | $20K | +0.0% | +5.6% | 0.0% | |
| Mar 2026 | $14K | +16.7% | +5.3% | 0.0% | |
| Mar 2026 | $14K | +7.7% | +5.3% | 0.0% | |
| Mar 2026 | $9K | +12.5% | +14.5% | 0.0% | |
CLYMClimb Bio, Inc. | Mar 2026 | $5K | -28.6% | +18.6% | 0.0% |
EVMNEvommune, Inc. | Mar 2026 | $4K | +300.0% | — | 0.0% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $3K | +0.0% | — | 0.0% |
| Peer median (excluding EVMN) | $14K | +4.2% | +7.1% | 0.0% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.